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Background: The purpose of this study was to evaluate the expression of claudin-3, claudin-7, and
claudin-18 in gastric cancer and to determine the signiﬁcance of these proteins for patient outcome.
Materials and methods: A total of 134 samples were obtained from surgically resected specimens from
patients who were diagnosed with gastric carcinoma at a single institution. Parafﬁn tissue sections from
tissue microarray blocks were examined with immunohistochemistry for the expression of claudin-3,
claudin-7, and claudin-18.
Results: In normal gastric tissues, positive immunoreactivity was detected for claudin-18 but not for
claudin-3 or claudin-7. Claudin-3 and claudin-7 were expressed in 25.4% and 29.9% of the gastric cancer
tissues, respectively. However, 51.5% of gastric cancer tissues exhibited reduced expression of claudin-18.
Claudin-7 expression was signiﬁcantly lower in cases with diffuse histologic type and positive lymphatic
invasion. There was a signiﬁcant inverse correlation between claudin-18 expression and perineural in-
vasion. In the survival analysis, the overall survival time was shorter in patients with claudin-7
expression than in those without claudin-7 expression. However, the overall survival was longer in
patients with claudin-18 expression than in those without claudin-18 expression.
Conclusions: Our data suggest that the up-regulation of claudin-3 and claudin-7 and the down-
regulation of claudin-18 may play a role in the carcinogenesis of gastric cancer. Furthermore, the
expression of claudin-7 and the loss of claudin-18 may be independent indicators of a poor prognosis in
patients with gastric cancer.
 2013 Surgical Associates Ltd. Published by Elsevier Ltd. All rights reserved.1. Introduction
Gastric cancer is the fourth most frequent malignancy and the
second most frequent cause of cancer death in East Asia and the
world.1 Although overall survival has improved in the last few
decades, the prognosis of patients with advanced gastric cancer
remains poor because tumor progression and metastasis of
gastric cancers occur frequently. Advancements have been made
in the molecular and histological analysis of most of the cancersSt. Vincent’s Hospital, The
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ciates Ltd. Published by Elsevier Ltarising from the gastrointestinal tract including esophageal,
gastric, and colon cancer.2,3 Despite these remarkable achieve-
ments, little diagnostic or therapeutic improvement for patients
with cancer recurrence or metastasis has resulted. Therefore,
there is a dire need for the identiﬁcation and characterization of
novel molecular markers that can be exploited for determining
prognosis.
Claudins, a crucial component of tight junctions, are trans-
membrane proteins with extracellular loops that are potential
targets for diagnostic and therapeutic modalities.4e6The alteration
in claudin expression might lead to impaired functioning tight
junction, have an inﬂuence on signaling pathways, and act as a
tumor promotional event in some epithelial cancer.7e9 Recent gene
expression proﬁling analyses have indicated that claudin gene
expression is altered in various cancers and claudin protein
expression may have signiﬁcant clinical relevance.10 Several
members of claudin family including claudin-3 and claudin-7 have
been reported to be more highly expressed in gastric cancerd. All rights reserved.
Table 1
Baseline clinical characteristics.
Basic characteristics Values (%)
Age (year) 63.47  11.64
Gender
Male 82 (61.2)
Female 52 (38.8)
Histologic type
Differentiated 71 (53.0)
Less-differentiated 63 (47.0)
Lauren classiﬁcation
Intestinal 70 (52.2)
Diffuse 51 (38.1)
Mixed 13 (9.7)
Lymphatic invasion
Positive 81 (60.4)
Negative 53 (39.6)
Venous invasion
Positive 30 (22.4)
Negative 104 (77.6)
Perineural invasion
Positive 55 (41.0)
Negative 79 (59.0)
T stage
T1 17 (12.7)
T2 24 (17.9)
T3 46 (34.3)
T4 47 (35.1)
N stage
N0 44 (32.8)
N1 20 (14.9)
N2 29 (21.6)
N3 41 (30.6)
M stage
M0 122 (91.0)
M1 12 (9.0)
TNM stage
I 25 (18.7)
II 42 (31.3)
III 55 (41.0)
IV 12 (9.0)
Total cases 134
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been reported to be more reduced in gastric cancer compared to
normal gastric mucosa.13 Claudin-low colon cancer is associated
with poor survival and this may be also true for gastric cancer.14Low
claudin-3 and claudin-18 protein expression was associated with
poorer survival in an analysis of 94 primary gastric adenocarci-
nomas.15 In contrast, in another study high claudin-3 expression in
gastric cancer was correlated with longer survival in both univari-
ate and multivariate analyses.16 Thus, deﬁnite correlation between
expression and clinical signiﬁcance of the claudin proteins in
gastric cancer remains controversial.
Unfortunately, studies on the prognostic signiﬁcance of these
claudins in gastric cancer have not been extensively studied. In this
study, we investigated the expression patterns of claudin-3, clau-
din-7, and claudin-18 in gastric cancer. In addition, we evaluated
the association of the expression of these proteins with the clini-
copathological characteristics of gastric cancer and assessed their
clinical signiﬁcance and prognostic value.Fig. 1. Immunohistochemicalanalysis of claudin-3, claudin-7, and claudin-18 in normal
gastric mucosa. Claudin-3 (A) and claudin-7 (B) are not detected in normal gastric
mucosa, however, intestinal metaplastic glands are positive for claudin-3 and claudin-
7 (inset)(100). (C) Expression of claudin-18 is preserved in gastric mucosa (100).2. Patients and methods
2.1. Patients
A total of 134 samples of primary gastric adenocarcinoma
were acquired from St. Vincent’s Hospital, The Catholic University
of Korea from March 2004 to May 2012. An additional 34samples
of non-cancerous gastric mucosa were included. The studyprotocol was approved by the Institutional Review Board of St.
Vincent’s Hospital, The Catholic University of Korea. The tumors
were divided into two histological subgroups: a differentiated
type consisting of papillary and well to moderately differentiated
tubular adenocarcinomas, and a less-differentiated type consist-
ing of poorly differentiated adenocarcinomas, signet ring cell
carcinomas, and mucinous adenocarcinomas. The stages of all of
the patients were evaluated in accordance with the guidelines of
the Japanese Classiﬁcation of gastric carcinoma.17The surgical
treatment comprised gastric resection, according to the locali-
zation of the primary tumor, and lymph node dissection
following the recommendations of the Japanese Research Society
for Gastric Cancer. After surgery, clinical follow-up data were
obtained from all of the patients. Survival time was measured as
the time from the date of the initial surgery to the date of death.
Fig. 2. Immunohistochemicalanalysis of claudin-3, claudin-7, and claudin-18 in gastric adenocarcinoma. (A) Claudin-3 shows negative expression in cancer cells (200). (B)
Claudin-7 shows negative expression in cancer cells (200). (C) Claudin-18 expression is preserved in gastric cancer cells (200). (D) Claudin-3 immunostainings show a strong
membranous pattern in cancer cells (200). (E)Claudin-7 immunostainings show a strong membranous pattern in cancer cells (200). (F) Reduced expression of claudin-18 shows
in cancer cells (200).
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were excluded from the study.
2.2. Construction of the tissue microarray (TMA) block
Formalin-ﬁxed parafﬁn-embedded tissues were obtained from
the subjects. Using hematoxylin and eosin (H&E)-stained slides, a
representative tumor site was chosen and the site corresponding
to the conﬁrmed tumor site in the parafﬁn block was marked.
Areas with necrosis, hemorrhage, or artifacts were excluded.
Single core biopsy specimens of 2 mm in diameter were taken
from the representative regions (SeongKohn Trader’s Co, Seoul,
Korea), placed on a TMA mold with 60 pores, and re-embedded
with parafﬁn. The TMA blocks were prepared as 4-mm-thick
sections and were stained with H&E. The tissues were then
examined to determine whether the appropriate tumor site had
been selected.
2.3. Immunohistochemistry
Immunohistochemical staining was performed on 4 mm sections
of the tissue microarray blocks using a manual procedure. The
parafﬁn sections were mounted on super frost glass slides, depar-
afﬁnized, and rehydrated with a graded series of ethanol, followed
by microwave antigen retrieval. Endogenous peroxidase activity
was blocked with 0.3% hydrogen peroxide. The sections were
incubated for 1 h or overnight at 4 C with a 1:100 dilution of a
primary rabbit polyclonal antibody against claudin-3 (Abcam,
Cambridge, MA, USA), claudin-7 (Abcam, Cambridge, MA, USA), and
claudin-18 (Novus, Littleton, CO, USA). Immunostaining was con-
ducted with the rabbit or mouse DAKO ChemMate EnVisionsystem, Peroxidase/DAB kit (DAKO, Glostrup, Denmark). The sec-
tions were then counterstained with Mayer’shematoxylin, dehy-
drated, cleared, and mounted. Normal intestinal mucosa was used
as a positive control for the anti-claudin-3 antibody and colon
cancer was used as a positive control forclaudin-7 and claudin-18.
All of the immunostained slides were evaluated independently
by two independent pathologists (J.J and H.C). The evaluation was
performed twice with the evaluator blinded as to the speciﬁc
diagnosis and prognosis of each individual case. Staining of cellular
membrane with the three antibodies was considered in the eval-
uation. Claudin-3 and claudin-7 staining were graded according to
the number of stained cells and the staining intensity of the indi-
vidual cells: negative, almost no positive cells or<10% of the tumor
cells had weak immunoreactivity; or positive, 10% of the tumor
cells had intense immunoreactivity. Claudin-18 staining was
considered to be ‘preserved’ if at least 50% of the cancer cells were
stained. When less than 50% of the cancer cells were stained, the
immunostaining was considered ‘reduced’. The immunohisto-
chemical staining was re-evaluated in cases where there was
disagreement between the pathologists. The two pathologists
reviewed those cases together, and reached an agreement for the
samples with inconclusive results.2.4. Statistical analysis
The results from the analysis of the continuous variables were
expressed as means  standard deviation (SD). The two-sided P
values were determined via Chi-square tests. The overall survival of
the patients was analyzed using KaplaneMeier methods with the
use of the log-rank test for univariate analysis. The Cox proportional
hazards model was used in the multivariate analysis of the factors
Table 2
Correlation between expression of claudin-3, -7, -18 and clinicopathological parameters.
Variables Cases no Claudin-3 expression Claudin-7 expression Claudin-18 expression
Negative Positive Negative Positive Preserved Reduced
Age
<60 46 34(73.9) 12(26.1) 37(80.4) 9(19.6) 19(41.3) 27(58.7)
60 88 66(75.0) 22(25.0) 57(64.8) 31(35.2) 46(52.3) 42(47.7)
p Value 0.891 0.060 0.228
Gender
Male 82 58(70.7) 24(29.3) 61(74.4) 21(25.6) 43(52.4) 39(47.6)
Female 52 42(80.8) 10(19.2) 33(63.5) 19(36.5) 22(42.3) 30(57.7)
p Value 0.193 0.178 0.253
Histologic type
Differentiated 71 51(71.8) 20(28.2) 45(63.4) 26(36.6) 37(52.1) 34(47.9)
Less-differentiated 63 49(77.8) 14(22.2) 49(77.8) 14(22.2) 28(44.4) 35(55.6)
p Value 0.430 0.069 0.375
Lauren classiﬁcation
Intestinal 70 51(72.9) 19(27.1) 42(60.0) 28(40.0) 38(54.3) 32(45.7)
Diffuse 51 41(80.4) 10(19.6) 41(80.4) 10(19.6) 22(43.1) 29(56.9)
Mixed 13 8(61.5) 5(38.5) 11(84.6) 2(15.4) 5(38.5) 8(61.5)
p Value 0.335 0.026 0.359
Lymphatic invasion
Absent 53 37(69.8) 16(30.2) 31(58.5) 22(41.5) 24(45.3) 29(54.7)
Present 81 63(77.8) 18(22.2) 63(77.8) 18(22.2) 41(50.6) 40(49.4)
p Value 0.300 0.017 0.546
Venous invasion
Absent 104 75(72.1) 29(27.9) 72(69.2) 32(30.8) 51(49.0) 53(51.0)
Present 30 25(83.3) 5(16.7) 22(73.3) 8(26.7) 14(46.7) 16(53.3)
p Value 0.214 0.665 0.819
Perineural invasion
Absent 79 55(69.5) 24(30.4) 53(67.1) 26(32.9) 44(55.7) 35(44.3)
Present 55 45(81.8) 10(18.2) 41(74.5) 14(25.5) 21(38.2) 34(61.8)
p Value 0.110 0.353 0.046
T stage
T1 17 14(82.4) 3(17.6) 13(76.5) 4(23.5) 8(47.1) 9(52.9)
T2 24 16(66.7) 8(33.3) 16(66.7) 8(33.3) 10(41.7) 14(58.3)
T3 46 32(69.6) 14(30.4) 33(71.7) 13(28.3) 22(47.8) 24(52.2)
T4 47 38(80.9) 9(19.1) 32(68.1) 15(31.9) 25(53.2) 22(46.8)
p Value 0.404 0.893 0.829
N stage
N0 44 33(75.0) 11(25.0) 30(68.2) 14(31.8) 23(52.3) 21(47.7)
N1-3 90 67(74.4) 23(25.6) 64(71.1) 26(28.9) 42(46.7) 48(53.3)
p Value 0.945 0.728 0.542
M stage
M0 122 90(73.8) 32(26.2) 84(68.9) 38(31.1) 59(48.4) 63(51.6)
M1 12 10(83.3) 2(16.7) 10(83.3.) 2(16.7) 6(50.0) 6(50.0)
p Value 0.468 0.296 0.914
TNM stage
I 25 19(76.0) 6(24.0) 18(72.0) 7(28.0) 12(48.0) 13(52.0)
II 42 29(69.0) 13(31.0) 28(66.7) 14(33.3) 21(50.0) 21(50.0)
III 55 42(76.4) 13(23.6) 38(69.1) 17(30.9) 26(47.3) 29(52.7)
IV 12 10(83.3) 2(16.7) 19(83.3) 2(16.7) 6(50.0) 6(50.0)
p Value 0.733 0.727 0.944
Values are presented as number (%).
*p < 0.05.
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univariate analysis. p < 0.05 was considered to indicate a statisti-
cally signiﬁcant difference with a 95% conﬁdence interval (95% CI).
3. Results
The clinicopathological data of our study population are pre-
sented in Table 1. Of the patients, 82 patients (61.2%) were men and
52 (38.8%) patients were women, with a mean age of 63.47  11.64
year (range, 27e85). Twenty-ﬁve (18.7%) patients had stage I, 42
(31.3%) patients had stage II, 55 (41.0%) patients had stage III, and 12
(9.0%) patients had stage IV cancer.
The microscopic features of the immunohistochemical staining
for each protein are presented in Figs. 1 and 2. In normal gastric
mucosa, positive immunoreactivity was detected for claudin-18 but
not for claudin-3 and claudin-7. Some intestinal metaplasticepithelia were positive for claudin-3 and claudin-7. Claudin-3 and
claudin-7 were expressed in 25.4% and 29.9% of the gastric cancer
tissues, respectively. However, 51.5% of the gastric cancer tissues
had reduced claudin-18 expression.
The results from the analysis of the correlation between the
expression of claudin-3, claudin-7, and claudin-18 and the clini-
copathological variables are presented in Table 2. The expression of
claudin-7 was signiﬁcantly higher in cases with intestinal type
adenocarcinoma based on the Lauren classiﬁcation (p ¼ 0.026) and
in cases without lymphatic invasion (p ¼ 0.017). Reduced claudin-
18 expression was signiﬁcantly correlated with perineural inva-
sion (p ¼ 0.046).
The survival analyses using the KaplaneMeier method with
regard to the clinicopathological variables and the expression
proﬁles of claudin-3, claudin-7, and claudin-18are summarized in
Table 3. Lymphatic invasion (p ¼ 0.006), vein invasion
Table 3
Univariate and multivariate analysis of clinicopathologic factors affecting survival
rate.
Variables 5-Year
survival
rate (%)
Univariate
analysis
p value
Multivariate analysis
Relative risk
(conﬁdence interval)
p Value
Age
<60 61.0 0.105 0.582 0.291
60 84.7 (0.213e1.590)
Gender
Male 74.9 0.352 0.524 0.178
Female 80.1 (0.204e1.343)
Histologic type
Differentiated 80.2 0.532 0.791 0.624
Less-differentiated 73.9 (0.310e2.018)
Lauren classiﬁcation
Intestinal 79.1 0.726 1.379 0.481
Diffuse 72.5 (0.564e3.375)
Mixed 82.1
Lymphatic invasion
Absent 92.9 0.006 1.793 0.417
Present 63.4 (0.438e7.335)
Venous invasion
Absent 85.0 0.000 4.614 0.001
Present 44.4 (1.872e11.372)
Perineural invasion
Absent 90.3 0.000 5.051 0.003
Present 59.7 (1.753e11.372)
T stage
T1 100
T2 67.4 0.004 1.276 0.498
T3 87.3 (0.630e2.586)
T4 63.7
N stage
N0 93.3 0.014 2.172 0.312
N1-3 69.0 (0.482e9.781)
M stage
M0 80.2 0.022 1.463 0.759
M1 34.9 (0.128e16.713)
TNM stage
I 100
II 84.8 0.008 0.649 0.530
III 67.0 (0.168e2.508)
IV 34.9
Claudin-3 expression
Negative 73.4 0.283 0.647 0.523
Positive 86.8 (0.170e2.460)
Claudin-7 expression
Negative 79.0 0.101 4.249 0.005
Positive 63.4 (1.544e11.693)
Claudin-18 expression
Preserved 90.5 0.082 3.186 0.029
Reduced 64.8 (1.127e9.008)
*p < 0.05.
Fig. 3. Survival curves of gastric cancer patients according to expression status of
claudin-7 (A) and claudin-18(B). There are signiﬁcant differences with regard to the
expression patterns of claudin-7 and claudin-18.
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(p ¼ 0.004), lymph node metastasis (p ¼ 0.014), and the TNM
stage (p ¼ 0.008) demonstrated a signiﬁcant correlation with
overall survival (OS). With regard to the 3 proteins analyzed, the
patients with claudin-7 expression had a shorter OS compared to
those without claudin-7 expression (5-year survival rate, 63.4%
versus 79.0%)(Fig. 3A). In contrast, the patients with reduced
expression of claudin-18 showed signiﬁcantly worse prognosis
than those with preserved expression of claudin-18 (5-year sur-
vival rate, 64.8% versus 90.5%)(Fig. 3B). However, overall survival
according to claudin-3 was not signiﬁcantly different (Fig. 3C).
Multivariate analysis using the Cox proportional hazards model
was performed to evaluate the independent prognostic pre-
dictors. As shown in Table 3, the independent prognostic factors
that were signiﬁcantly associated with OS in patients with gastric
cancer were venous invasion (p ¼ 0.001) and perineural invasion
(p ¼ 0.003). In addition, the expression of claudin-7 (p ¼ 0.005)and loss of claudin-18 (p ¼ 0.029) were found to be statistically
signiﬁcant prognostic factors.4. Discussion
Claudins comprise a multigene family of 27 species and
constitute the backbone of the tight junctions that are implicated in
K.-H. Jun et al. / International Journal of Surgery 12 (2014) 156e162 161
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differentially expressed claudin family members in cancer cells has
been reported in previous studies.16,18The overexpression or the
loss of expression of speciﬁc claudin species plays an important role
in various malignant diseases.19e21
In this study, we determined the expression of claudin-3, clau-
din-7, and claudin-18 in 134gastric cancer tissue samples with the
goal of achieving a more precise understanding of the associations
of the expression of these proteins expressions with the clinico-
pathological characteristics and survival. In this study, we found
that claudin-3 and claudin-7 expression was up-regulated not only
in cancer cells, but also in intestinal metaplasia, while claudin-18
expression was down-regulated in gastric cancer. These ﬁndings
are consistent with previous reports.12,22e25 Notably, we observed a
signiﬁcantly higher frequency of claudin-7 expression in cases with
intestinal type adenocarcinoma than in those with diffuse type or
mixed type, which is consistent with the results obtained by
Johnson et al.16 and Park et al.26 and in contrast with those of Erika
et al.25 who found that claudin-7 was expressed mainly in the
diffuse type. Regarding the histogenesis of gastric cancer, it has
generally been concluded that the differentiated type (intestinal
type) carcinomas arise from areas of intestinal metaplasia, whereas
undifferentiated (diffuse type) lesions originate from normal
gastric mucosa.3 Therefore, the results that intestinal metaplastic
cells and intestinal-type gastric cancer cells expressed highly
claudin-7 may support the theory of a carcinogenesis process that
progresses from intestinal metaplasia to adenoma to intestinal-
type gastric cancer.
Cluadin-18 was ﬁrst identiﬁed as a downstream target gene of
the T/EBP/NKX2.1 homeodomain transcription factor.13A recent
study indicates that claudin-18 is highly expressed in normal
gastric cells and down-regulation of this expression is observed in
57.5% of gastric cancers.24In our study, we found that normal gastric
tissues expressed claudin-18, however, 51.5% of gastric cancers
showed reduced claudin-18 expression. Moreover, claudin-18
expression was lower in cases with perineural invasion than in
those without perineural invasion, which is a marker for a poor
prognosis. These ﬁndings suggest that loss of claudin-18 may be
related to the aggressive behavior of gastric cancer as well as gastric
carcinogenesis. However, further studies are warranted to examine
the usefulness of claudin-18 as a prognostic indicator.
There have been few studies reporting the association of sur-
vival outcomes with the expression of claudin family members in
gastric cancer. Soini et al.16reported that claudin-3 expression was
associated with a better prognosis of the patients, especially those
with the intestinal type cancer. Matsuda et al.12 demonstrated that
the classiﬁcation of gastric cancers using gastric and intestinal
claudins is a good biomarker for assessing the risk of poor prog-
nosis. In a previous study, we demonstrated that tumors expressing
claudin-4 were associated with a good prognosis, although we
were not able to report 5-year survival results due to the short
follow-up periods.27 In the present study, claudin-7 and claudin-18
had independent prognostic values. Claudin-7 expression was
signiﬁcantly associated with a poorer prognosis of the patients,
while the preserved expression of claudin-18was signiﬁcantly
associated with a better prognosis. Our results suggested that the
expression proﬁles of claudin-7 and claudin-18 may be useful
prognostic markers in gastric cancer, although this proposal should
be studied further to obtain deﬁnitive evidence.
Our study has some limitations. First, the clinicopathological
characteristics among the cohorts were dissimilar in some pa-
rameters. The main reason for these discrepancies is that we con-
ducted a retrospective cohort study to evaluate prognostic
signiﬁcance of claudin-3, claudin-7, and claudin-18. Second, this
study has a limitation stemming from its rather small sample size.Third, only the immunohistochemical method was adopted to
determine the expressions of claudin-3, claudin-7, and claudin-18.
Our results could provide further rationale for its continued
investigation in future in vitro study.
In conclusion, the increased expression of claudin-3 and
claudin-7 and the reduced expression of claudin-18 may play a role
in the carcinogenesis of gastric cancer. Moreover, the expression of
claudin-7 and the loss of claudin-18 in gastric cancer may be in-
dependent markers of a poor prognosis. These ﬁndings warrant
additional molecular and clinicopathological studies of these
markers and their related pathways which are potentially relevant
to the prognosis of gastric cancer.
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